Ratna Karuna

Ratna Karuna

Auto-generated profile, based on publicly available information

Ratna Karuna

Novartis Institute for Tropical Diseases, Singapore

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2011 in Nature
Verified
Journal Article
Closed access
PDF file
SHSébastien Hannedouche
Sébastien Hannedouche
JZJuan Zhang
Juan Zhang
TYTangsheng Yi
Tangsheng Yi
WSWeijun Shen
Weijun Shen
DNDeborah Nguyen
Deborah Nguyen
ASAndreas Sailer
Andreas Sailer

15 August 2015 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
QWQing-Yin Wang
Qing-Yin Wang
HDHongping Dong
Hongping Dong
BZBin Zou
Bin Zou
RKRatna Karuna
Ratna Karuna
KWKah Fei Wan
Kah Fei Wan
PSPei-Yong Shi
Pei-Yong Shi
The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo . The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC 50 ], 10 to 80 nM) but not DENV-1 and -4 (EC 50 , >20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients. IMPORTANCE Dengue virus (DENV) threatens up to 2.5 billion people and is now spreading in many regions in the world where it was not previously endemic. While there are several promising vaccine candidates in clinical trials, approved vaccines or antivirals are not yet available. Here we describe the identification and characterization of a spiropyrazolopyridone as a novel inhibitor of DENV by targeting the viral NS4B protein. The compound potently inhibits two of the four serotypes of DENV (DENV-2 and -3) both in vitro and in vivo . Our results validate, for the first time, that NS4B inhibitors could potentially be developed for antiviral therapy for treatment of DENV infection in humans.

3 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMStephanie Anne Moquin
Stephanie Anne Moquin
OSOliver Simon
Oliver Simon
RKRatna Karuna
Ratna Karuna
SLSuresh B. Lakshminarayana
Suresh B. Lakshminarayana
FYFumiaki Yokokawa
Fumiaki Yokokawa
FGFeng Gu
Feng Gu
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.

8 April 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FYFumiaki Yokokawa
Fumiaki Yokokawa
SNShahul Nilar
Shahul Nilar
CNChristian G. Noble
Christian G. Noble
SLSiew Pheng Lim
Siew Pheng Lim
RRRanga Rao
Ranga Rao
PSPaul W. Smith
Paul W. Smith

1 December 2011 in Atherosclerosis
Verified
Journal Article
Closed access
RKRatna Karuna
Ratna Karuna
RPRebekka Park
Rebekka Park
AOAlaa Othman
Alaa Othman
AHAdriaan G Holleboom
Adriaan G Holleboom
MMMohammad Mahdi Motazacker
Mohammad Mahdi Motazacker
AEArnold von Eckardstein
Arnold von Eckardstein

1 February 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
YCYen-Liang Chen
Yen-Liang Chen
NGNahdiyah Abdul Ghafar
Nahdiyah Abdul Ghafar
RKRatna Karuna
Ratna Karuna
YFYilong Fu
Yilong Fu
SLSiew Pheng Lim
Siew Pheng Lim
PSPei-Yong Shi
Pei-Yong Shi
In a recent clinical trial, balapiravir, a prodrug of a cytidine analog (R1479), failed to achieve efficacy (reducing viremia after treatment) in dengue patients, although the plasma trough concentration of R1479 remained above the 50% effective concentration (EC 50 ). Here, we report experimental evidence to explain the discrepancy between the in vitro and in vivo results and its implication for drug development. R1479 lost its potency by 125-fold when balapiravir was used to treat primary human peripheral blood mononuclear cells (PBMCs; one of the major cells targeted for viral replication) that were preinfected with dengue virus. The elevated EC 50 was greater than the plasma trough concentration of R1479 observed in dengue patients treated with balapiravir and could possibly explain the efficacy failure. Mechanistically, dengue virus infection triggered PBMCs to generate cytokines, which decreased their efficiency of conversion of R1479 to its triphosphate form (the active antiviral ingredient), resulting in decreased antiviral potency. In contrast to the cytidine-based compound R1479, the potency of an adenosine-based inhibitor of dengue virus (NITD008) was much less affected. Taken together, our results demonstrate that viral infection in patients before treatment could significantly affect the conversion of the prodrug to its active form; such an effect should be calculated when estimating the dose efficacious for humans.